Today, I review, link to, and excerpt from The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease [PubMed Abstract] [Full-Text HTML] [Full-Text PDF]. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.
There are 101 similar articles in PubMed.
The above article has been cited by 4,978 articles in PubMed.
All that follows is from the above article.
- Title & authors
- Abstract
- Conflict of interest statement
- Comment in
- Similar articles
- Cited by
- References
- Publication types
- MeSH terms
- Substances
- Grants and funding
- LinkOut – more resources
Abstract
The National Institute on Aging and the Alzheimer’s Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer’s disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.
Keywords: Mild cognitive impairment, AD dementia, Diagnosis
